Improve outcomes through next-generation sequencing

Guiding treatment for more patients

While monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can block the growth and spread ofcolorectal cancer, studies have shown that tumors with specific gene mutations will not respond to these therapies. Based on internal Mayo Clinic data, Mayo Clinic Laboratories’ expanded genetic panel identified 24% more patients who are unlikely to benefit from EGFR-targeted therapy.

Because of the potential for increased toxicity and cost, identification of individuals most likely to respond to targeted therapies is essential for appropriate patient management. Our next-generation sequencing panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.


Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.


Key testing

MCCRC | MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor

Provides optimized testing for patients with colorectal cancer (CRC) by sequencing:

  • APC
  • BRAF 
  • HRAS 
  • KRAS
  • MLH1 
  • MSH2 
  • MSH6 
  • NRAS 
  • PMS2

Also provides microsatellite instability (MSI) status

Additional testing

KRASD | Cell-Free DNA KRAS 12, 13, 61,146, Blood

  • Offers cell-free DNA testing on peripheral blood when tumor testing is not available for CRC patients.
  • Detects the presence of common KRAS mutations at codons 12, 13, 61, and 146.

Anti-PDL1 immunotherapy

Anti-PD-L1 immunotherapies such as pembrolizumab have recently emerged as a therapeutic option in CRC. These therapies are designed to block the PD-L1/PD-1 immune checkpoint pathway, thereby assisting the immune system in tumor cell detection. However, current data indicates that only patients with defective-mismatch repair (MMR) and/or high-microsatellite instability (MSI) are likely to benefit from this therapy. Our rapid tumor microsatellite instability (TMSI) evaluation is the only clinically available assay of its kind to offer fast test results.

Key testing


A Test in Focus

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Learn more about how to order these evaluations at your institution.